Prime Capital Investment Advisors LLC Purchases 249 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Prime Capital Investment Advisors LLC raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,654 shares of the biotechnology company’s stock after buying an additional 249 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $1,081,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Innealta Capital LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics during the first quarter worth $32,000. Nkcfo LLC acquired a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $43,000. Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the last quarter. Finally, UMB Bank n.a. increased its position in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 197 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $109.11 on Friday. The company has a market capitalization of $10.42 billion, a price-to-earnings ratio of 87.29 and a beta of 0.81. The firm’s 50 day simple moving average is $124.21 and its 200 day simple moving average is $132.49. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25.

Insiders Place Their Bets

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Raymond James reiterated an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Guggenheim increased their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $181.33.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.